摘要
目的探讨国产程序性细胞死亡蛋白-1(programmed death-1,PD-1)抑制剂联合仑伐替尼治疗老年晚期肝癌患者的临床疗效及安全性。方法收集2021年9月~2022年7月于郑州颐和医院接受国产PD-1抑制剂联合仑伐替尼治疗的37例老年(60岁以上)晚期肝癌患者的临床资料,采用实体瘤改良疗效评价标准(Modified Response Evaluation Criteria in Solid Tumors,mRECIST)评价肝内病灶疗效,采用实体瘤疗效评价标准(Response Evaluation Criteria in Solid Tumors,RECIST)1.1版评价转移灶疗效。采用Kaplan-Meier法绘制生存曲线。结果37例老年晚期肝癌患者中,肿瘤部分缓解8例,疾病稳定15例,肿瘤进展14例,客观缓解率和疾病控制率分别为21.6%(8/37)和62.2%(23/37),中位无进展生存期为5.885个月(95%CI:5.374~6.397个月)。总体治疗相关不良反应的发生率为51.4%(19/37),疲乏27.0%(10/37)、皮疹27.0%(10/37)和高血压21.6%(8/37)是最常见的不良反应。结论国产PD-1抑制剂联合仑伐替尼治疗老年晚期肝癌疗效可,安全性好。
Objective To explore the clinical efficacy and safety of domestic programmed death-1(PD-1)ingibitor combined with lenvatinib in the treatment of advanced hepatocellular carcinoma in the elderly.Methods The clinical data of 37 elderly patients(over 60 years old)with advanced hepatocellular carcinoma,who received domestic PD-1 inhibitors combined with lenvatinib in Zhengzhou Yihe Hospital from September 2021 to July 2022 were collected.Modified Response Evaluation Criteria in Solid Tumors(mRECIST)was used to evaluate the efficacy of intrahepatic lesions,and Response Evaluation Criteria in Solid Tumors(RECIST)1.1 was used to evaluate the efficacy of extrahepatic metastatic lesions.Kaplan-Meier method was used to evaluate the survival curve.Results Among the 37 elderly patients with hepatocellular carcinoma,8 patients achieved partial response,15 patients achieved stabilization,and 14 patients achieved disease progression.The objective response rate and the disease control rate were 21.6%(8/37)and 62.2%(23/37),respectively,and the median progression-free survival time was 5.885months(95%CI:5.374-6.397 months).The overall incidence rate of treatment-related adverse events was 51.4%(19/37).The most common adverse events were fatigue 27.0%(10/37),rash 27.0%(10/37)and hypertension 21.6%(8/37).Conclusion Domestic PD-1 inhibitors combined with lenvatinib is an effective and safe therapy for elderly patients with advanced hepatocellular carcinoma.
作者
于丹丹
王黎
袁惠芳
潘静
连慧娟
YU Dandan;WANG Li;YUAN Huifang(Department of Oncology,Zhengzhou Yihe Hospital,Henan 450000,China)
出处
《医学研究杂志》
2024年第2期156-159,共4页
Journal of Medical Research
